Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Pollack R, Raz I, Wiviott SD, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Mosenzon O, Langkilde AM, Gause-Nilsson IAM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Cahn A.
Pollack R, et al. Among authors: cahn a.
Diabetes Care. 2023 Jan 1;46(1):156-164. doi: 10.2337/dc22-1318.
Diabetes Care. 2023.
PMID: 36399721
Clinical Trial.